Edap Tms’ (EDAP) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Edap Tms (NASDAQ:EDAP) in a report released on Monday morning. The brokerage currently has a $6.50 price objective on the medical equipment provider’s stock.
“We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: (1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and (2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property.”,” the firm’s analyst wrote.
Several other equities research analysts also recently weighed in on EDAP. Zacks Investment Research raised shares of Edap Tms from a sell rating to a hold rating in a report on Tuesday, April 10th. ValuEngine downgraded shares of Edap Tms from a hold rating to a sell rating in a report on Wednesday, May 2nd. Finally, TheStreet downgraded shares of Edap Tms from a c rating to a d+ rating in a report on Tuesday, May 15th.
Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Monday, May 14th. The medical equipment provider reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.05. The business had revenue of $11.28 million during the quarter, compared to the consensus estimate of $10.46 million. Edap Tms had a negative net margin of 5.98% and a negative return on equity of 5.89%. research analysts anticipate that Edap Tms will post -0.01 EPS for the current fiscal year.
A hedge fund recently raised its stake in Edap Tms stock. Archon Capital Management LLC raised its position in shares of Edap Tms SA (NASDAQ:EDAP) by 7.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,019,011 shares of the medical equipment provider’s stock after buying an additional 71,336 shares during the quarter. Edap Tms accounts for 0.2% of Archon Capital Management LLC’s portfolio, making the stock its 14th largest position. Archon Capital Management LLC owned about 3.51% of Edap Tms worth $2,364,000 as of its most recent filing with the Securities and Exchange Commission. 9.67% of the stock is currently owned by hedge funds and other institutional investors.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.